

Endocyte, Inc. Logo

## Endocyte to Present at the Cowen and Company 38th Annual Health Care Conference

March 5, 2018

WEST LAFAYETTE, March 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company's management team will present at the Cowen and Company 38<sup>th</sup> Annual Health Care Conference on Monday, March 12<sup>th</sup> at 2:50 p.m. EDT.

A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at [www.endocyte.com](http://www.endocyte.com). The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.

### About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, <sup>177</sup>Lu-PSMA-617, entering Phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR-T therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at [www.endocyte.com](http://www.endocyte.com).

### Investor Contact:

Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [stephanie@sternir.com](mailto:stephanie@sternir.com)

 [Primary Logo](#)

Source: Endocyte, Inc.